# Zanzalintinib in Unresectable and Progressive MPGGs

> **NCT07714551** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 14 (estimated)

## Conditions studied

- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07714551
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-09
- **Primary completion:** 2031-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714551, "Zanzalintinib in Unresectable and Progressive MPGGs". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*